Investment Q&A

Q: Hi Peter and Staff
If I am correct, I believe you were high on DXCM at one point and may not feel as high on it today? It had gone up nicely until recent earnings but downward spiral since then. Is it closer to a buy or a sell in a basket of health care stocks .
Secondly, assuming it might be deemed not as good as some or all of the following,, please rank the top 4 in order from
ABBV, CRRX, ISRG,MDT,SYK,VEEV and WELL

THanks for all you do
Dennis

Q: Good afternoon folks
BNTX has been doing very well as of late. I am up 35% ish. Also my entire health sector weighting is 6.85%...all US$...BNTX is 2% of this total. I also own MDT, DXCM, ZTS, GH, & VEEV. I have too many stocks in general throughout all sectors and am trying to sell off several slowly but surely. ( I have 66 stocks). The problem being I fall in love with each of them...(yes....very bad I know)...as they have mostly been carefully chosen and watched over almost every day.
My question is should I sell all of my BNTX or shave but sell any of the others mentioned above,
Thanks as always for your sound advice.

Q: Hello Peter,
I have partial positions in AVLR and DXCM and have been considering AFRM and CRNC.
I think that the potential for CRNC is further on the time frame, while AFRM has to demonstrate its growth potential in the next couple of quarters. Dexcom has to confirm its growth whereas AVLR has to demonstrate that it can still grow to justify the valuation. What do you think?
Now I cannot own everything that is of interest and would like your opinion on whether I should in my portfolio have a full position in one of them or partial positions in two. And which one, or two would you suggest?
Regards
Rajiv

Q: Hi Peter and Staff

FInally bite the bullet on Sienna, looking to redeploy in the US topping up some or all of my US basket of health care. Please eliminate any of the above that you do not feel are a buy at this time and rank the rest within categories of strong buy, buy or hold.
Thanks for all you do
Dennis

Q: Hi Peter,
The market did not take kindly to the revenue guidance for 2021 even if the growth rate would be 20%? Were the expectations from Europe much higher than what the company expects? What is your view? With its current valuation and projected growth, would you expect the stock price to stagnate? Unless they promise low and deliver over?

Q: Hello Peter,
From what I have been reading: The cash positions within pension and other investment funds is at historically low levels. The trend over the past few weeks has been a shift from growth and technology to cyclical and value stocks.
On the flip side, the technology sector generally does well to start the new year.
I have done well with growth stocks mostly in the tech sector and have a couple of holdouts such as DXCM, AYX GH that have not performed. And I am also fully invested.
Should I look to raise cash by trimming my gains, which would be in tech, mostly US except for some CAD such as DSG, LSPD OTEX etc? Or, should I sell the growth holdouts for cash? Should I even raise cash and invest in cyclicals and value such as TT, RTX, US financials or any other you may suggest. Or should I just ride the growth portfolio into January and spring of 2021?
Looking for your magic eight ball answer.
Regards
Rajiv

Q: Do you endorse a tax-loss sale for these three stocks, DXCM, REAL, VHI with the intention to buy back after 30 days? Are there any that you wouldn't buy back and instead use the proceeds on another high growth name such as NVDA, U, GOOS, PINS, MGNI? Sector weighting is not a concern and risk tolerance is high. Thanks.

Q: Back in May I asked a question about DXCM. It was in the low $400's then and it has since fallen to the low $300's. Do you know the reason for the decline and what do you think of it now? How "expensive" is it now/would you buy? (I never ended up getting any and am thinking of stepping in now)

Q: Hello Peter,
I would like your assessment of DXCM after the earnings call. The growth rate has not tapered, the valuation on P/E and P/B looks to be in line with growth companies such as CRWD, VEEV etc. The product has now access to the european market, which probably was not part of the equation earlier quarter. Apart from the impending retirement of a senior executive, what would cause the sharp drop relative to the market?
Would this be a candidate for capital loss sale and buy in Dec or Jan?
Look forward to your thoughts.
Regards
Rajiv

Q: I currently have PFE, GILD, MDT and ABBV in my Healthcare sector. I am looking to add a couple of names - I have been looking at MRK and BMY - your opinion please on these AND can you provide some other US healthcare companies that might be of interest to you at this time. Greatly appreciate your comments.
Thanks

Q: Good day,
Wells Fargo analyst downgraded DXCM in addition to lowering its price target from $420 to $350. Has anything drastically changed and is it still worth holding? Thanks

Q: Currently hold VEEV and GH in the health care space. Considering MDT as the next addition. What do you think of this. Any better suggestions?

Q: Given the recent corrections, what are some names (Canada and US) you would add? Thanks!

Q: Hi, thanks for your great service. I am interested in investing in healthcare sector - specifically continuous glucose monitoring devices - US and International. What would be your top stock choices in this area and why? 3 year hold. Thanks again.

Q: Hi
This company is giving 12% dividend. is it sustainable? and please give your thought on this. is it buy?
and please give top 5 US growth stocks for three yrs hold.
Thank you,
KT

Q: What is your top choice for playing the gold sector? This will be my only exposure to precious metals.

What are your top 10 growth names (Canada or US) for a new investment with a minimum 5 year hold? I'm not concerned about sector diversity or weighting because we're well diversified in other, larger parts of our portfolio.

Thanks.

Q: Hi
Could you please compare Abbott and Dexcom. I am hopeful that the Diabetic Glucose Monitors market will be profitable. I think I am not alone with this giving the valuation of DXCM...,or would ABT win the comparison on size, diversity, etc.? Thank you for helping us out with your insight.

Q: Good morning team,

In a bit of a portfolio cleanup in my TFSA yesterday I sold some laggards and reduced my Shopify shares to bring it more in line with my targeted weighting. After completing Norbert's Gambit, I will be deploying the funds to buy US stocks. Please share your 2 or 3 favourite growth stocks for 5+ year hold in each of the following categories: Health Care, Communication Services, and other non-Tech (if you have more compelling options than those listed in Health and Comm Service).

Thanks in advance,
Rory

Q: What would be your top 3 stock selections in the large cap medical device space for long term capital appreciation. Thank-you.

Q: Hello Peter,
While SQ holds the promise when the retailers open, it does not really matter for PYPL. Which one would you suggest.
In your presentation at the MoneyShow yesterday you mentioned DXCOM in the healthcare sector with an increasing demand, company raising guidance and now being included in the index.
If I were to take a position in it, I will not be able to have positions in both SQ and PYPL. Which of these two would you suggest I let go.
Or would you suggest I hold them both and take a pass at DXCM instead.
As always, your opinion is appreciated.
Regards.